Keeping Abreast charity backing Kickstarter campaign for…

Sue Pringle founder of Mille Lingerie with her new Millie bra designed to be comfortable for women who have undergone breast reconstruction surgery. Picture: REBECCA LEWIS A Norwich charity is backing a fundraising campaign to develop a bra specially designed for women who have undergone breast reconstruction surgery.

TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol

TiGenix NV , an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has received positive feedback from the U.S. Food and Drug Administration on an improved protocol for its global Phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients.

Correcting and Replacing Biocad: The first ever biosimilar of interferon beta-1a approved in Russia

The Ministry of Health of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Merck’s RebifA that is a key component in treatment of relapsing-remitting multiple sclerosis and included in all international recommendations and protocols. BIOCAD started the development program for interferon beta-1a biosimilar in 2012 and it took almost 5 years to run all the development phases, including pre-clinical/clinical studies and registration.

Oticon raises awareness of how hearing loss treatment can have positive effect on quality of life

Hearing Loss is the number one cause of years lived with disability for people over 70. In Europe, more than 51 million people suffer from hearing loss, and these numbers will only continue to grow. On World Hearing Day, Oticon, an industry leader in advanced audiology and hearing aid technology, raises awareness of how treatment for hearing loss can have a positive effect on quality of life in both everyday and work situations.

APR Applied Pharma Research and DKSH Bring Innovative Migraine and Pain Treatment to Asian Patients

APR Applied Pharma Research s.a. , the Swiss, independent developer of science driven, patent protected healthcare products, is today proud to announce the business partnership with DKSH, the leading Market Expansion Services provider with a focus on Asia. The partnership involves marketing, sales, distribution and logistics for APR’s patented Diclofenac 50 mg powder oral solution for acute migraine treatment and other pain areas, in Malaysia, the Philippines, Myanmar and Vietnam under the DKSH subsidiary Favorex.

Highmark Spoofs Patients With So. Many. Questions Marketing Daily a ” 9 minutes ago

It’s a phenomenon that gets worse with every birthday: The average doctor’s visit gets shorter, while patients’ list of health problems gets longer. So Highmark, the fourth-largest Blue Cross Blue Shield-affiliated health insurance provider, is introducing a new ad campaign that pokes gentle fun at the growing list of health worries that follow people as they sail into their Medicare years.

Melinta Therapeutics and Menarini Group Enter into Commercial and…

Melinta Therapeutics , a privately held company developing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced the signing of a development and commercialization agreement. As part of this agreement, Melinta has granted the Menarini Group exclusive rights to commercialize Delafloxacin , an investigational anionic fluoroquinolone, under their own brands in 68 countries in Europe, Asia-Pacific including China, South Korea, and Australia , and the Commonwealth of Independent States including Russia.

Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments

Santen, Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., the specialty ophthalmology company headquartered in Osaka, Japan, and twoXAR, Inc., an artificial intelligence-driven biopharmaceutical company, today announced that the two companies have entered into a strategic research collaboration focused on the identification of new drug candidates for glaucoma. Under the agreement, twoXAR will use its proprietary computational drug discovery platform to discover, screen, and prioritize novel drug candidates with potential application in ocular indications, with a specific focus on glaucoma.

Celltrion’s Rituxan biosimilar wins Eur…

South Korea’s Celltrion announced Wednesday that the European Medicines Agency has granted sales approval to Truxima, its biosimilar drug referencing Roche’s blockbuster lymphatic cancer drug Rituxan. Truxima is the first ever Rituxan biosimilar to be approved by the European drug regulator, as well as the first ever Europe-approved biosimilar monoclonal antibody used to target cancer.

Takeda and TiGenix Report New Data Highlighting Maintenance of…

Takeda Pharmaceutical Company Limited and TiGenix NV today announced new data from the Phase 3 ADMIRE-CD clinical trial, which indicated that investigational compound Cx601, a suspension of allogeneic adipose-derived stem cells , maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.[1] Results were presented at the 12th Congress of the European Crohn’s and Colitis Organisation .

Dress like Ed Sheeran for under A 37k? St Elizabeth Hospice and ‘Young Ed’ can help

Hugo Fairbanks Weston, who played “Young Ed” in Ed Sheeran’s Castle on the Hill video is modelling the singer’s old clothes, which will be auctioned by St Elizabeth Hospice. Picture: ST ELIZABETH HOSPICE The sixth-form student who played a young Ed Sheeran in the video for his Suffolk “love song” has followed in the star’s charitable footsteps – quite literally – by wearing some of his old shoes and clothes.

Hikma signs Easyhaler deal with Orion

Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Finland’s Orion for its new Easyhaler combination product for the treatment of asthma and chronic obstructive pulmonary disease. Under the terms of the agreement, Hikma has the exclusive rights to register, distribute, market and sell the product in all of its MENA markets, leveraging the company’s local presence, sales and marketing capabilities and regulatory expertise.

‘Morning Glories’ Gets New Marketing Boost

The story Mash shares in “Morning Glories” gives readers the courage to know that it is okay to let go. While dealing with the death of a close family member, Tracey A. Mash was inspired to write ” Morning Glories ” in hope of encouraging others that death is not the final chapter for love.

Teaching Tobacco

… yrockets for top performers! Other channels seek to redefine convenience! The economy enters a new stage. The growing health-and-wellness trend. Fuel demand; oil’s slide; multicultural momentum; and data, data, data!

CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

SCI reported the net income available to common shareholders for the quarter ended December 31, 2016 was $3,536,802 or $0.02 per basic share, versus $2,341,813 or $0.02 per basic share during the quarter ended December 31, 2015. CEL-SCI reported an operating loss of for the quarter ended December 31, 2016 versus an operating loss of for the quarter ended December 31, 2015.